澳大利亚50-64岁成人全国流感疫苗接种计划预防住院成本的成本效益分析
本研究从政府视角对澳大利亚50-64岁成人扩大政府资助流感疫苗接种计划进行成本效益分析,参数来自公开数据库和已发表文献。多数节省来自避免的急性心肌梗死住院,但结果对疫苗接种管理成本和疫苗有效性估计敏感。
要点
- 扩大国家免疫规划至50-64岁成人可能具有成本效益,基础情景增量效益成本比1.40。
- 节省主要来自避免的急性心肌梗死住院,而非呼吸道住院。
- 药师参与疫苗接种可能降低管理成本,改善成本效益。
核心结论
- 将国家免疫规划扩展至50-64岁成人可能对政府具有成本效益,但结论对疫苗管理成本和疫苗有效性估计敏感。
研究设计与样本
- 从政府视角的成本效益分析,参数来自公开数据库和已发表文献。
主要发现
- 基础情景下每年预防314例流感/肺炎住院、388例其他呼吸道住院和1482例急性心肌梗死住院。
- 多数节省来自避免的急性心肌梗死住院。
临床怎么用
- 支持将国家免疫规划扩展至50-64岁成人以预防流感相关住院并节省政府成本。
- 考虑增加药师在免疫规划中的作用以降低疫苗管理成本。
局限性
- 结果对疫苗管理成本(通过全科医生或药师提供)和疫苗有效性估计的变化敏感。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Influenza causes a significant burden among Australian adults aged 50-64, however, vaccine coverage rates remain suboptimal. The National Immunisation Program (NIP) currently funds influenza vaccinations in this age group only for those at high risk of influenza complications. AIMS: The main aim of this study was to determine whether a strategy of expanding the government-funded vaccination program to all adults 50-64 in preventing influenza-related hospitalisations will be cost beneficial to the government. METHODS: A cost-benefit analysis from a governmental perspective was performed using parameters informed by publicly available databases and published literature. Costs included cost of vaccinations and general practitioner consultation while benefits included the savings from averted respiratory and acute myocardial infarction (AMI) hospitalisations. RESULTS: In the base-case scenario, the proposed policy would prevent 314 influenza/pneumonia, 388 other respiratory and 1482 AMI hospitalisations in a year. The government would save $8.03 million with an incremental benefit-cost ratio of 1.40. Most savings were due to averted AMI hospitalisations. In alternative scenarios cost savings ranged from saving of $31.4 million to additional cost to the government of $15.4 million, with sensitive variation in vaccine administration practices (through general practitioner or pharmacists) and vaccine effectiveness estimates. DISCUSSION: Extension of the NIP to include adults 50-64 years of age is likely to be cost beneficial to the government, although this finding is sensitive to vaccine administration cost, which varies if provided through general practitioners or pharmacists; and to variation in vaccine effectiveness. An increased role of pharmacists in immunisation programs would likely result in cost savings in an expanded adult immunisation program.
引用
- Raj SM, Chughtai AA, Sharma A, et al. Cost-benefit analysis of a national influenza vaccination program in preventing hospitalisation costs in Australian adults aged 50-64 years old. Vaccine. 2019. PMID: 31473001. doi:10.1016/j.vaccine.2019.08.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。